Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Effects of arsenic compounds on apoptosis, cell cycle
and DNA methylation on myelodysplastic syndromes cells and leukemia cells

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: TANAKA, Sachiko (Tokyo University Of Phramacy And Life Sciences, Hachioji, Japan)
  • Co-author(s): Sachiko Tanaka: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Fang Su : National Therapeutic Center of Hematology of Traditional Chinese Medicine, XiYuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
    Qing-Bing Zhou: National Therapeutic Center of Hematology of Traditional Chinese Medicine, XiYuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
    Hu Xiaomei: National Therapeutic Center of Hematology of Traditional Chinese Medicine, XiYuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
    Kenji Onda: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Taku Furukawa: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Kentaro Sugiyama: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Anna Kiyomi: Department of Drug Safety Management, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Hironori Takeuchi: Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Sakae Unezaki: Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Haruki Yamada: Department of Kampo Medicines, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Takao Akashi: Department of Pharmaceutics, Tokyo Medical University, Tokyo, Japan
    Toshihiko Hirano: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
  • Abstract:

    Backgrounds

    Arsenic has been used for the treatment of malignant hematologic diseases including Myelodysplastic syndromes (MDS), which are a group of clonal disorders of haematopoietic stem cells characterised by ineffective haematopoiesis and a tendency to evolve into acute myeloid leukaemia (AML). Arsenic trioxide (As2O3) has been confirmed to be ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses